非高密度脂蛋白胆固醇与心脑血管疾病关系研究进展

摘要/Abstract

摘要： 非高密度脂蛋白胆固醇（non-high-density lipoprotein cholesterol， non-HDL-C）反映致动脉粥样硬化胆固醇的总量，美国国家胆固醇教育计划中的成人治疗专家方案第3号报告中首次提出这一概念，并且将其作为降脂治疗的第二目标。目前已广泛证实non-HDL-C在冠状动脉粥样硬化性心脏病发病率及死亡率方面的预测价值较高，甚至可能优于传统血脂指标。但non-HDL-C与脑血管病相关的研究有限且结果存在争议，本文就non-HDL-C与心脑血管病相关的研究现状做一综述。

文章导读： 非高密度脂蛋白胆固醇与心脑血管疾病关系密切，关注其在心脑血管病发生和发展过程中的作用有益于心脑血管疾病的防治。

关键词: 非高密度脂蛋白胆固醇; 低密度脂蛋白胆固醇; 动脉粥样硬化; 心血管疾病; 脑血管疾病

Abstract: Non-high-density lipoprotein cholesterol (non-HDL-C) reflects the total amount of atherogenic cholesterol. The concept of non-HDL-C was first proposed on the National Cholesteral Education Program Adult Treatment Panel III and was assigned to be the second target for lipid- lowering therapy. More and more recent studies at home and abroad have shown that the non- HDL-C could be a more accurate predictor of morbidity and morality of coronary atherosclerotic heart disease than traditional markers such as low density lipoprotein cholesterol. Currently, there are less and scattered research on the association between non-HDL-C and cerebrovascular diseases. This review aims to summarize and analyze the research progress of non-HDL-C.

Key words: Non-high-density lipoprotein cholesterol; Low density lipoprotein cholesterol; Atherosclerosis; Cardiovascular diseases; Cerebrovascular diseases

刘洋，郭阳. 非高密度脂蛋白胆固醇与心脑血管疾病关系研究进展[J]. 中国卒中杂志, 2015, 10(09): 799-803.

LIU Yang, GUO Yang. . Research Progress on Non-High-Density Lipoprotein Cholesteral and Cardiovascular and Cerebrovascular Diseases [J]. Chinese Journal of Stroke, 2015, 10(09): 799-803.

参考文献

1 National Cholesterol Education Program Expert Panel.
Executive summary of the third report of the National
Cholesterol Education Program (NCEP) Expert Panel
on detection, evaluation, and treatment of high blood
cholesterol in adults (Adults Treatment Panel III)[J].
JAMA, 2001,285:2486-2497.
2 Miller M, Stone NJ, Ballantyne C, et al. Triglycerides
and cardiovascular disease[J]. Circulation, 2011,
123:2292-2333.
3 Allan S, Matt M, John C, et al. Why is non-high-
density lipoprotein cholesterol a better marker of the
risk of vascular disease than low-density lipoproteincholesterol[J]. J Clin Lipidol, 2010, 4:152-155.
4 Rabar S, Harker M, O'Flynn N, et al. Lipid
modification and cardiovascular risk assessment
for the primary and secondary prevention of
cardiovascular disease:summary of updated NICE
guidance[J]. BMJ, 2014, 349:356.
5 Stone NJ, Robinson J, Lichtenstein AH, et al. 2013
ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular
risk in adults:a report of the American College of
Cardiology/American Heart Association Task Force
on Practice Guidelines[J]. J Am Coll Cardiol, 2013,
63:3024-3025.
6 Wu J, Chen S, Zhou Y, et al. Non-high-density
lipoprotein cholesterol on the risks of stroke:a result
from the Kailuan study[J]. PLoS One, 2013, 8:e74634.
7 Wu J, Chen S, Liu L, et a1. Non-high-density lipoprotein
cholesterol vs low-demity lipoprotein cholesterol as a
risk factor for ischemic stroke:a result from the Kailuan
study[J]. Neurol Res, 2013, 35:505-511.
8 Yun KH, Jeong MH, Oh SK, et al. The beneficial
effect of high loading dose of rosuvastatin before
percutaneous coronary intervention in patients
with acute coronary syndrome[J]. Int Cardiol, 2009,
137:246-251.9 付文金, 彭兰芬, 叶长钦, 等. 非高密度脂蛋白胆固醇
与传统血脂指标的相关性分析[J]. 国际检验医学杂志,
2007, 28:705-707.
10 Study of the Effectiveness Additional Reductions
in Cholesterol and Homocysteine (SEARCH)
Collaborative Group. Intensive lowering of LDL
cholesterol with 80 mg versus 20 mg simvastatin daily
in 12 064 survivors of myocardial infarction:a double-
blind randomized trial[J]. Lancet, 2010, 376:1658-
1669.
11 Lloyd-Jones D, Adams RJ, Brown TM, et al.
Executive summary:heart disease and stroke
statistics-2010 update:a report from the American
Heart Association[J]. Circulation, 2010, 121:948-954.
12 Lju J, Sempos CT, Donahue RP, et a1. Non-high-
density lipoprotein and very-low-density lipoprotein
cholesterol and their risk predictive values in coronary
heart disease[J]. Am J Cardiol, 2005, 98:1363-1368.
13 Pischon T, Girman CJ, Sacks FM, et a1. Non-high-
density lipoprotein cholesterol and apolipoprotein B
in the prediction of coronary heart disease in men[J].
Circulation, 2005, 112:3375-3383.
14 Bittner V. Non-high-density lipoprotein cholesterol
and cardiovascular disease[J]. Cur Opin Lipidol, 2003,
140:367-371.
15 Arsenault BJ, Rana JS, Stroes ES, et al. Beyondlow-density lipoprotein cholesterol:respective
contributions of non-high-density lipoprotein
cholesterol levels, triglycerides and the total
cholesterol high-density lipoprotein cholesterol ratio
to coronary heart disease risk in apparently healthy
men and women[J]. J Am Coll Cardiol, 2009, 55:35-41.
16 许海燕, 乔树宾, 张家芬, 等. 非高密度脂蛋白胆固醇
对冠状动脉病变的影响[J]. 中国动脉硬化杂志, 2010,
18:409-411.
17 Tsuyoshi I, Yasufumi D, Toshiharu N, et al. Non-high-
density lipoprotein cholesterol and the development
of coronary heart disease and stroke subtypes in a
general Japanese population:The Hisayama Study[J]. J
Atherosclerosis, 2014, 233:343-348.
18 Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical
utility of different lipid measures for prediction of
coronary heart disease in men and women[J]. JAMA,
2007, 298:776-785.
19 Liu J, Sempos CT, Donahue RP, et al. Non-high
density lipoprotein and very-low-density lipoprotein
cholesterol and their risk predictive values in coronary
heart disease[J]. Am J Cardiol, 2006, 98:1363-1368.
20 Rallidisa LS, Pitsavosb C, Panagiotakos DB, et al.
Non-high density lipoprotein cholesterol is the bestdiscriminator of myocardial infarction in young
individuals[J]. Atherosclerosis, 2005, 179:305-309.
21 刘影, 帅平, 刘玉萍. 非高密度脂蛋白胆固醇与颈
动脉血管病变相关性分析[J]. 实用医学杂志, 2013,
29:2515-2516.
22 Wu J, Zhang Q, Yang H, et a1. Association between
non-high-density lipoprotein cholesterol levels and
the prevalence of asymptomatic intracranial arterial
stenosis[J]. PLoS One, 2013, 8:e65229.
23 Liu M, Wu B, Wang WZ, et al. Stroke in
China:epidemiology, prevention, and management
strategies[J]. J Lancet Neurol, 2007, 6:456-464.
24 Di Angelantonio E, Sarwar N, Perry P, et a1. Major
lipids, apolipoproteins, and risk of vascular disease[J].
JAMA, 2009, 302:1993-2000.
25 Mahajan N, Ferenee B, Arora N, et a1. Role of non-
high-density lipoprotein cholesterol in predicting
cerebrovascular events in patients following
myocardial infarction[J]. Am J Cardiol, 2012,
109:1694-1699.
26 Tanabe N, Iso H, Okada I, et a1. Serum total and
non-high-density lipoprotein cholesterol and the risk
prediction of cardiovascular events-the JALS_ECC[J].
Circ J, 2010, 74:1346-1356.

[1]	伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170.
[2]	刘伊桐, 黄燕琪, 李明利, 冯逢, 高山, 徐蔚海. 颈动脉几何形态——60岁及以下无高危因素人群颅内动脉粥样硬化的潜在预测指标[J]. 中国卒中杂志, 2022, 17(09): 925-931.
[3]	龚宇田, 黎洁洁. IL-6和动脉粥样硬化性缺血性卒中的关系研究进展[J]. 中国卒中杂志, 2022, 17(09): 1022-1026.
[4]	雷延成, 刘著, 王进鹏, 张豪, 杨文芳, 肖顺熙, 杨慧洁, 莫海珍, 陈燕. 高海拔地区缺血性卒中患者单核细胞/HDL-C比值与脑动脉粥样硬化性狭窄的相关性 [J]. 中国卒中杂志, 2022, 17(08): 829-833.
[5]	中国卒中学会神经介入分会. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J]. 中国卒中杂志, 2022, 17(08): 863-888.
[6]	张倩, 张冠一, 张佳, 陈胜云, 赵性泉. 空腹血糖对无症状颈动脉粥样硬化斑块患者认知功能的影响—— 1项针对非城镇居民的调查[J]. 中国卒中杂志, 2022, 17(07): 753-757.
[7]	凌一童, 孙玉杰, 李广文, 刘彤晖, 李野, 张勇. 雷帕霉素洗脱支架与金属裸支架治疗症状性颅内动脉粥样硬化性狭窄的效果比较[J]. 中国卒中杂志, 2022, 17(05): 529-534.
[8]	莫东灿, 刘柳余, 李肖玲, 李建立, 罗曼. 模式生物斑马鱼在卒中研究中的应用[J]. 中国卒中杂志, 2022, 17(05): 548-552.
[9]	瓮佳旭, 仇鑫, 李子孝. TET2突变相关不确定潜能的克隆性造血与卒中发生发展的研究进展[J]. 中国卒中杂志, 2022, 17(04): 413-417.
[10]	李昕, 张英魁, 曹康熙, 袁庆海. 1例青年卒中患者的多模态影像检查[J]. 中国卒中杂志, 2022, 17(03): 314-317.
[11]	霍晓川, 贺红卫, 缪中荣. 合并颅内动脉粥样硬化性狭窄的机械取栓治疗1例——取栓支架内膜剥脱[J]. 中国卒中杂志, 2021, 16(11): 1099-1101.
[12]	胡建刚, 廖文楷, 郑勇, 宋建勋, 叶华卫, 黄居科. HR-MRI血管壁成像在不同年龄大脑中动脉急性闭塞患者机械取栓术后的诊疗价值研究[J]. 中国卒中杂志, 2021, 16(11): 1150-1155.
[13]	闫然, 上官艺, 仇鑫, 李子孝. DNA甲基化酶3A在动脉粥样硬化中的作用机制[J]. 中国卒中杂志, 2021, 16(11): 1178-1182.
[14]	王一轻, 刘平国, 沈佳慧, 蔡增林. 脑穿支动脉病变梗死类型和神经影像学研究进展[J]. 中国卒中杂志, 2021, 16(09): 877-882.
[15]	北京神经科学学会血管神经病学专业委员会, 阿加曲班治疗急性缺血性卒中中国专家共识组. 阿加曲班治疗急性缺血性卒中中国专家共识2021[J]. 中国卒中杂志, 2021, 16(09): 946-953.